El producto es el primer tratamiento semanal sin factor para la hemofilia B SILVER SPRING, Md., 11 de octubre de 2024 /PRNewswire-HISPANIC PR WIRE/– Hoy, la Administración de Alimentos y Medicamentos (FDA, por sus siglas en inglés) aprobó Hympavzi (marstacimab-hncq) para la profilaxis de…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.